Comparative Pharmacology
Head-to-head clinical analysis: NELARABINE versus NIPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NELARABINE versus NIPENT.
NELARABINE vs NIPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
None Documented
None Documented
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNelarabine + Deslanoside
"Nelarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNelarabine + Acetyldigitoxin
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent